FDA's announcement describes its approval of a higher-dose Wegovy product containing semaglutide under the agency's national-priority voucher program. 1
This update reports the regulatory action and links to FDA's announcement. It does not restate indications, compare products, or provide treatment guidance. 1
What this source can tell us. PeptideScanner is reporting the cited regulator or label record. The summary does not extend that record into broader safety, effectiveness, or approval claims.